Lilly/Incyte’s baricitinib shows additional benefit in hospitalized COVID-19 patients

Eli Lilly (LLY-0.5%) and its collaborating partner Incyte (INCY+0.1%) have announced additional efficacy and safety data from Adaptive COVID-19 treatment trial (ACTT-2), demonstrating baricitinib in … [read more]

Leave a Comment